Takeda Enters into a License Agreement with Selecta to Develop Gene Therapies for the Treatment of Lysosomal Storage Disorders
Shots:
- Selecta to receive up front and ~$1.124B upon the achievement of development or commercial milestones or Takeda’s election continue its activities at specified development stages. Selecta is also eligible to receive royalties on future commercial sales
- The collaboration will utilize Selecta’s ImmTOR platform that accelerates transgene expression and addresses AAV vector immunogenicity to deliver transformative therapies for two indications
- ImmTOR has the potential to amplify the efficacy of biologic therapies- including redosing of gene therapies- restore the body’s natural self-tolerance in autoimmune diseases & can induce tolerance to highly immunogenic proteins
| Ref: Selecta | Image: Takeda
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com